Can pharmacokinetic and pharmacodynamic principles be applied to the treatment of multidrug-resistant Acinetobacter?

Annals of Pharmacotherapy

Volumn 45, Issue 2, 2011, Pages 229-240

  Cooper, Travis W ^a,b   Pass, Steven E ^c   Brouse, Sara D ^c   Hall II, Ronald G ^c  

^a PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c TEXAS TECH UNIVERSITY   (United States)

Author keywords

Acinetobacter; Multidrug resistance; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMIKACIN; CARBAPENEM; CEFTAZIDIME; COLISTIN; DORIPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; MINOCYCLINE; NETILMICIN; RIFAMPICIN; SULPERAZON; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAM; POLYMYXIN; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE;

ACINETOBACTER; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTEREMIA; DRUG ACTIVITY; DRUG HALF LIFE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; OSTEOMYELITIS; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; VENTILATOR ASSOCIATED PNEUMONIA; CROSS INFECTION; DRUG COMBINATION;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HUMANS; POLYMYXINS; TETRACYCLINES;

EID: 79951880812     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P187     Document Type: Review

References (112)

1. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:3471-84. DOI 10.1128/AAC.01464-06 (Pubitemid 47519332)
2. Davis KA, Moran KA, McAllister CK, Gray PJ. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis 2005; 11:1218-24. (Pubitemid 41045329)
3. Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2005;11:22-9. (Pubitemid 40093348)
4. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41:848-54. DOI 10.1086/432803 (Pubitemid 41266753)
5. Navon-Venezia S, Ben-Ami R, Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005;18:306-13. (Pubitemid 41017634)
6. Turton JF, Kaufmann ME, Warner M, et al. A prevalent, multiresistant clone of Acinetobacter baumannii in Southeast England. J Hosp Infect 2004;58:170-9. DOI 10.1016/j.jhin.2004.05.011 (Pubitemid 39462583)
7. Paterson DL. Serious infections in the intensive care unit: Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 2006;43:S41-42. DOI 10.1086/504473
8. Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents 2008;32:29-32. DOI 10.1016/j.ijantimicag.2008.02.016
9. Gootz TD, Marra A. Acinetobacter baumannii: an emerging multidrug-resistant threat. Expert Rev Anti Infect Ther 2008;6:309-25. DOI 10.1586/14787210.6.3.309
10. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008; 46:1254-63. DOI 10.1086/529198 (Pubitemid 351589912)
11. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial- resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996-1011. DOI 10.1086/591861
12. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12. DOI 10.1086/595011
13. Nicasio AM, Kuti JL, Nicolau DP. The current state of multidrug-resistant gram-negative bacilli in North America. Pharmacotherapy 2008; 28:235-49. DOI 10.1592/phco.28.2.235
14. Cisneros JM, Reyes MJ, Pachon J, et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996;22:1026-32. (Pubitemid 26260606)
15. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111-8. DOI 10.1086/374337 (Pubitemid 36549630)
16. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002;34: 1425-30. DOI 10.1086/340055 (Pubitemid 34553700)
17. Jellison TK, McKinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem- cilastatin or ampicillin-sulbactam. Pharmacotherapy 2001;21:142-8. DOI 10.1592/phco.21.2.142.34114 (Pubitemid 32120147)
18. Jimenez-Mejias ME, Pachon J, Becerril B, Palomino-Nicas J, Rodriguez- Cobacho A, Revuelta M. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin Infect Dis 1997;24:932-5. (Pubitemid 27193880)
19. Cawley MJ, Suh C, Lee S, Ackerman BH. Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis. Pharmacotherapy 2002;22:527-32. DOI 10.1592/phco.22.7.527.33676 (Pubitemid 34270038)
20. Levin AS, Levy CE, Manrique AE, Medeiros EA, Costa SF. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 2003;21:58-62. DOI 10.1016/S0924-8579(02)00276-5 (Pubitemid 36043975)
21. Urban C, Go E, Mariano N, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993;167:448-51. (Pubitemid 23036450)
22. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/ sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008;61:1369-75. DOI 10.1093/jac/dkn128 (Pubitemid 351753609)
23. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008;56:432-6. DOI 10.1016/j.jinf.2008.04.002
24. Gounden R, Bamford C, van Zyl-Smit R, Cohen K, Maartens G. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 2009;9:26. DOI 10.1186/1471-2334-9-26
25. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11. DOI 10.1086/514732 (Pubitemid 29203530)
26. Motaouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006;53:274-8. (Pubitemid 44391062)
27. Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008;61:417-20. DOI 10.1093/jac/dkm509
28. Wood GC, Hanes SD, Boucher BA, Croce MA, Fabian TC. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator- associated pneumonia. Intensive Care Med 2003;29:2072-6. (Pubitemid 37487143)
29. Griffith ME, Yun HC, Horvath LL, Murray CK. Minocycline therapy for traumatic wound infections caused by multidrug-resistant Acinetobacter baumannii-calcoaceticus complex. Infect Dis Clin Pract 2008;16:16-9. DOI 10.1097/ipc.0b013e318159d595
30. Vasilev K, Reshedko G, Orasan R, et al. A Phase 3, open-label, noncomparative study of tigecycline in the treatment of patients with selected serious infections due to resistant gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62(suppl 1):i29-40. DOI 10.1093/jac/dkn249
31. Curcio D, Fernandez F, Cane A, Barcelona L, Stamboulian D. Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry. Braz J Infect Dis 2008;12:198-201. DOI 10.1590/S1413-86702008000300007
32. Gallagher JC, Rouse HM. Tigecycline for the treatment of Acinetobacter infections: a case series. Ann Pharmacother 2008;42:1188-94. DOI 10.1345/aph.1L171
33. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008;36:1089-96. DOI 10.1097/CCM.0b013e3181691b99 (Pubitemid 351482655)
34. Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006;40:219-23. DOI 10.1345/aph.1G467 (Pubitemid 43269850)
35. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005;49:1337-9. DOI 10.1128/AAC.49.4.1337-1339.2005 (Pubitemid 40463358)
36. Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother 2005;49:461-3. DOI 10.1128/AAC.49.1.461-463.2005 (Pubitemid 40065834)
37. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009;64:142-50. DOI 10.1093/jac/dkp139
38. Wang H, Zhang B, Ni Y, et al. Pharmacodynamic target attainment of seven antimicrobials against gram-negative bacteria collected from China in 2003 and 2004. Int J Antimicrob Agents 2007;30:452-7. DOI 10.1016/j.ijantimicag.2007.06. 005 (Pubitemid 47498959)
39. Tam VH, Ledesma KR, Vo G, Kabbara S, Lim TP, Nikolaou M. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrob Agents Chemother 2008;52: 3987-93. DOI 10.1128/AAC.01468-07
40. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010;54:4503-5. DOI 10.1128/AAC.01707-09
41. Jaruratanasirikul S, Sudsai T. Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion. J Antimicrob Chemother 2009;63: 560-3. DOI 10.1093/jac/dkn543
42. Nicholson SC, Peterson J, Ambruzs M, Yektashenas B, Xiang J. Doripenem 1 g infused for 4 hours (h) in the treatment of nosocomial pneumonia/ventilator associated pneumonia (NP/VAP) due to Acinetobacter baumannii (A. baumannii) (abstract 386). In: 47th Annual Meeting of the Infectious Diseases Society of America, October 29-November 1, 2009, Philadelphia, PA.
43. Burkhardt O, Derendorf H, Welte T. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother 2007;8:237-56. DOI 10.1517/14656566.8.2.237 (Pubitemid 46206625)
44. Craig WA, Ebert SC. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 1992;36:2577-83.
45. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10. DOI 10.1086/516284
46. Vondracek TG. Beta-lactam antibiotics: is continuous infusion the preferred method of administration? Ann Pharmacother 1995;29:415-24.
47. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003;17:479-501. (Pubitemid 38029149)
48. Drusano GL. Pharmacokinetic optimization of beta-lactams for the treatment of ventilator-associated pneumonia. Eur Respir Rev 2007;16:45-49. DOI 10.1183/09059180.00010304 (Pubitemid 47312075)
49. Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther 2004;26:493-501. DOI 10.1016/S0149-2918(04)90051-3 (Pubitemid 38586450)
50. Stroup JS, Mitchell K, Hitzeman D. Novel treatment approach to combat an infection with Acinetobacter. Proc (Bayl Univ Med Cent) 2010; 23:29-30.
51. Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains nonfermentative gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents 2003; 22:551-6. DOI 10.1016/S0924-8579(03) 00245-0
52. Ling TK, Ying CM, Lee CC, Liu ZK. Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong. Med Princ Pract 2005; 14:338-41. DOI 10.1159/000086932 (Pubitemid 41161009)
53. Pennington JE. Penetration of antibiotics into respiratory secretions. Rev Infect Dis 1981;3:67-73.
54. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam- aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997;41:1127-33. (Pubitemid 27194197)
55. Noone P, Pattison JR, Davies DG. The effective use of gentamicin in life-threatening sepsis. Postgrad Med J 1974;50(suppl 7):9-16.
56. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-9. (Pubitemid 17225088)
57. Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother 1985;15(suppl A):37-46. DOI 10.1093/jac/15.suppl-A.37 (Pubitemid 15079546)
58. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987;31:1054-60. (Pubitemid 17099578)
59. Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008; 30:674-81. DOI 10.1097/FTD.0b013e31818b6b2f
60. Traynor AM, Nafziger AN, Bertino JS, Jr. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 1995; 39:545-8.
61. Zaske DE, Chin T, Kohls PR, Solem LD, Strate RG. Initial dosage regimens of gentamicin in patients with burns. J Burn Care Rehabil 1991; 12:46-50.
62. Tatman-Otkun M, Gurcan S, Ozer B, Shokrylanbaran N. Annual trends in antibiotic resistance of nosocomial Acinetobacter baumannii strains and the effect of synergistic antibiotic combinations. New Microbiol 2004;27:21-8. (Pubitemid 40091024)
63. Savov E, Chankova D, Vatcheva R, Dinev N. In vitro investigation of the susceptibility of Acinetobacter baumannii strains isolated from clinical specimens to ampicillin/sulbactam alone and in combination with amikacin. Int J Antimicrob Agents 2002;20:390-392. DOI 10.1016/S0924-8579(02)00207-8
64. Le Conte P, Potel G, Peltier P, et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis 1993;147:1279-82. (Pubitemid 23149891)
65. Ioannidou E, Siempos, II, Falagas ME. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 2007;60:1216-26. DOI 10.1093/jac/dkm385 (Pubitemid 350168316)
66. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 2009;65:431-4. DOI 10.1016/j.diagmicrobio.2009.07.018
67. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, twentieth informational supplement. January 2010. M100-S20. Vol 30(1).
68. Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003;52:987-92. DOI 10.1093/jac/dkg468 (Pubitemid 38008420)
69. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6. DOI 10.1128/AAC.01361-08
70. Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008; 30:143-51. DOI 10.1016/j.clinthera.2008.01.015 (Pubitemid 351834728)
71. Plachouras D, Giamarellos-Bourboulis EJ, Kentepozidis N, Baziaka F, Karagianni V, Giamarellou H. In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2007;57:419-22. DOI 10.1016/j.diagmicrobio.2006.10.006
72. Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007;59:473-7. DOI 10.1093/jac/dkl512
73. Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/ pharmacodynamic model. Antimicrob Agents Chemother 2007;51:3413-5. DOI 10.1128/AAC.01571-06 (Pubitemid 350067568)
74. Li J, Rayner CR, Nation RL, et al. Heteroresistance to colistin in multidrug- resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006;50:2946-50. DOI 10.1128/AAC.00103-06 (Pubitemid 44396396)
75. Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 2008;52:351-2. DOI 10.1128/AAC.00766-07
76. Tan TY, Ng LS, Tan E, Huang G. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007;60:421-3. DOI 10.1093/jac/dkm178
77. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006;27:224-8. DOI 10.1016/j.ijantimicag.2005.10.012
78. Ullman MA, Hovde LB, Rotschafer JC. Sequential dosing of colistin sulfate plus an extended infusion of doripenem is effective against multidrug- resistant Acinetobacter baumannii and carbapenemase-producing Klebsiella pneumoniae (abstract A1-571). In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2009, San Francisco, CA.
79. Shields RK, Potoski BA, Clancy CJ, et al. Microbiologic and clinical evidence supporting the combination of doripenem and colistin for the treatment of pan-resistant Acinetobacter (abstract E-1459). In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2009, San Francisco, CA.
80. Pachon-Ibanez ME, Docobo-Perez F, Lopez-Rojas R, et al. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010;54:1165-72. DOI 10.1128/AAC.00367-09
81. Song JY, Lee J, Heo JY, et al. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2008;32:281-4. DOI 10.1016/j.ijantimicag.2008.04.013
82. Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010;35:194-9. DOI 10.1016/j.ijantimicag.2009.10.005
83. Falagas ME, Sideri G, Vouloumanou EK, Papadatos JH, Kafetzis DA. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J 2009;28:123-7. DOI 10.1097/INF. 0b013e31818a5dbd
84. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008;14:816-27. DOI 10.1111/j.1469-0691.2008.02061.x
85. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53-9. DOI 10.1186/cc3020
86. Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrugresistant gram-negative bacteria: a prospective study. Respir Med 2008; 102:407-12. DOI 10.1016/j.rmed.2007.10.011 (Pubitemid 351179979)
87. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41. DOI 10.1086/429323 (Pubitemid 40570245)
88. MedWatch. 2007 Safety information alert: colistimethate (marketed as Coly-Mycin M and generic products). http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm124896.pdf (accessed 2011 Feb 3).
89. Fernandez-Viladrich P, Corbella X, Corral L, Tubau F, Mateu A. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis 1999;28:916-7. DOI 10.1086/517243 (Pubitemid 29169442)
90. Dudhani RV, Li J, Turnidge JD, Nation RL. In vivo pharmacodynamics of colistin against Acinetobacter baumannii in murine thigh and lung infection models (abstract A1-572). In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2009, San Francisco, CA.
91. Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;51:3781-8. DOI 10.1128/AAC.01533-06 (Pubitemid 350057771)
92. Pachon-Ibanez ME, Fernandez-Cuenca F, Docobo-Perez F, Pachon J, Pascual A. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother 2006;58: 689-92. DOI 10.1093/jac/dkl303 (Pubitemid 44288142)
93. Hogg GM, Barr JG, Webb CH. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 1998;41:494-5. DOI 10.1093/jac/41.4.494
94. Tascini C, Menichetti F, Bozza S, Del Favero A, Bistoni F. Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother 1998;42:270-1. DOI 10.1093/jac/42.2.270 (Pubitemid 28393603)
95. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2001;40:117-20. DOI 10.1016/S0732-8893(01)00258-9 (Pubitemid 32735549)
96. Song JY, Kee SY, Hwang IS, et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 60:317-22. DOI 10.1093/jac/dkm136
97. Pantopoulou A, Giamarellos-Bourboulis EJ, Raftogannis M, et al. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 2007;29:51-5. DOI 10.1016/j.ijantimicag.2006.09.009 (Pubitemid 44959789)
98. Yoon J, Urban C, Terzian C, Mariano N, Rahal JJ. In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004;48:753-7. DOI 10.1128/AAC.48.3.753-757.2004
99. Petrosillo N, Chinello P, Proietti MF, et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 2005;11:682-3. DOI 10.1111/j.1469-0691.2005.01198.x (Pubitemid 41051389)
100. Song JY, Cheong HJ, Lee J, Sung AK, Kim WJ. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents 2009;33:33-9. DOI 10.1016/j.ijantimicag.2008.07.008
101. Saballs M, Pujol M, Tubau F, et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2006;58:697-700. DOI 10.1093/jac/dkl274 (Pubitemid 44288144)
102. Scheetz MH, Qi C, Warren JR, et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem- intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:1621-6. DOI 10.1128/AAC.01099-06
103. Dizbay M, Tozlu DK, Cirak MY, Isik Y, Ozdemir K, Arman D. In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii. J Antibiot (Tokyo) 2010;63:51-3. DOI 10.1038/ja.2009.117
104. Koomanachai P, Kim A, Nicolau DP. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. J Antimicrob Chemother 2009;63:982-7. DOI 10.1093/jac/dkp056
105. Schafer JJ, Mangino JE. Multidrug-resistant Acinetobacter baumannii osteomyelitis from Iraq. Emerg Infect Dis 2008;14:512-4. (Pubitemid 351451411)
106. Ambrose PG, Bhavnani SM, Owens RC Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 2003;17:529-43. DOI 10.1016/S0891-5520(03) 00061-8 (Pubitemid 38029151)
107. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005;55:601-7. DOI 10.1093/jac/dki079 (Pubitemid 40691835)
108. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004;189:1590-7. DOI 10.1086/383320 (Pubitemid 38648286)
109. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-81. (Pubitemid 23141323)
110. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003;47:1681-8. DOI 10.1128/AAC.47.5.1681-1688.2003
111. Vila J, Ribera A, Marco F, et al. Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2002;49:471-7. DOI 10.1093/jac/49.3.471 (Pubitemid 34223668)
112. DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy 2007;27:333-42. DOI 10.1592/phco.27.3.333